Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Chinese Patients With Focal-Onset Seizures: An Observational, Prospective Study

被引:17
|
作者
Zhang, Ranran [1 ]
Qiao, Shan [2 ]
Fang, Xiqin [1 ]
Wang, Kemo [1 ]
Shi, Yanting [1 ]
Du, Qianwen [1 ]
Yang, Tingting [1 ]
Liu, Xuewu [1 ,3 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Neurol, Jinan, Peoples R China
[2] Shandong First Med Univ, Affiliated Hosp 1, Dept Neurol, Jinan, Peoples R China
[3] Shandong Univ, Inst Epilepsy, Jinan, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2021年 / 12卷
基金
中国国家自然科学基金;
关键词
epilepsy; anti-seizure medication; focal seizures; perampanel; seizure freedom; ILAE COMMISSION; POSITION PAPER; REAL-LIFE; EPILEPSY; CLASSIFICATION; SAFETY;
D O I
10.3389/fneur.2021.731566
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To evaluate the efficacy and tolerability of adjunctive perampanel (PER) in Chinese patients with focal-onset seizures, with or without secondarily generalized tonic-clonic seizures.</p> Methods: Fifty-six patients aged 14-72 years were recruited consecutively in this single-center prospective observational study. All patients received PER as add-on treatment on the basis of clinical judgment. Seizure frequency, adverse events (AEs), and retention rates were obtained at 3 and 6 months after PER introduction.</p> Results: The overall response rates were 60 and 71.1% after 3 and 6 months, respectively, and the freedom of seizures at the same points were reached in 8 and 15.8%. The retention rates were 89.3% at the 3-month follow-up and 67.9% at the 6-month follow-up. The overall incidence of adverse events was 55.4%. The leading reported AEs were dizziness (39.3%) and somnolence (25%).</p> Conclusions: Our study confirmed the efficacy and tolerability of adjunctive PER in Chinese patients in real-life conditions. Based on our treatment experience, a lower maintenance dose of PER would be needed in Chinese patients.</p>
引用
收藏
页数:8
相关论文
共 50 条
  • [41] A mirroring clinical practice study of perampanel in adults and adolescents: Assessment of the impact of perampanel on quality of life and sleep in patients with focal-onset seizures
    Assenza, G.
    Gambardella, A.
    Goldman, S.
    Patten, A.
    Chiacchiaretta, M.
    Gentile, A.
    EPILEPSIA, 2022, 63 : 125 - 125
  • [42] Real-world experience of perampanel monotherapy in epilepsy patients with focal-onset and generalised-onset seizures
    Alsaadi, T.
    Toledo, M.
    Ayuga Loro, F.
    Trinka, E.
    Wu, T.
    Malhotra, M.
    Ngo, L. Y.
    Gil-Nagel, A.
    Villanueva, V.
    EPILEPSIA, 2022, 63 : 12 - 12
  • [43] Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Refractory Epilepsy
    Barr, Donald
    Gomez, Francisco
    Castillo, Richard
    Kirmani, Batool
    NEUROLOGY, 2019, 92 (15)
  • [44] Safety and effectiveness of perampanel monotherapy after adjunctive therapy through retention rate in subjects with focal-onset seizures with or without focal to bilateral tonic-clonic seizures: A multicenter retrospective study in Korea
    Lim, Sung Chul
    Lee, Won Gu
    Kim, Dong Wook
    Kim, Kwang Ki
    Shon, Young -Min
    Park, Jihyun
    Lee, Yoona
    Seo, Dae-Won
    EPILEPSY & BEHAVIOR, 2023, 145
  • [45] EFFECTIVENESS OF PERAMPANEL AS ADJUNCTIVE THERAPY IN PATIENTS WITH REFRACTORY FOCAL SEIZURES WITH GCI ASSESSMENT
    De Maria, G.
    Rinaldi, F.
    Milan, A.
    EPILEPSIA, 2016, 57 : 175 - 175
  • [46] REAL-WORLD EXPERIENCE OF PERAMPANEL MONOTHERAPY IN EPILEPSY PATIENTS WITH FOCAL-ONSET AND GENERALISED-ONSET SEIZURES
    Alsaadi, Taoufik
    Toledo, Manuel
    Loro, Fernando Ayuga
    Trinka, Eugen
    Wu, Tony
    Malhotra, Manoj
    Ngo, Leock Y.
    Gil-Nagel, Antonio
    Villanueva, Vicente
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [47] Real-World Experience of Perampanel Monotherapy in Epilepsy Patients with Focal-Onset and Generalized-Onset Seizures
    Alsaadi, Taoufik
    Toledo, Manuel
    Loro, Fernando Ayuga
    Trinka, Eugen
    Wu, Tony
    Malhotra, Manoj
    Ngo, Leock Y.
    Gil-Nagel, Antonio
    Villanueva, Vicente
    NEUROLOGY, 2022, 98 (18)
  • [48] Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension
    Nishida, Takuji
    Lee, Sang Kun
    Inoue, Yushi
    Saeki, Kazunori
    Ishikawa, Kohei
    Malhotra, Manoj
    Patten, Anna
    Kaneko, Sunao
    EPILEPSIA OPEN, 2024, 9 (02) : 501 - 512
  • [49] Adjunctive Perampanel and Levetiracetam in Patients with Focal-Onset Seizures Co-administered With/Without Enzyme-Inducing Anti-Seizure Medications
    Goldman, Samantha
    Ngo, Leock Y.
    Patten, Anna
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 58 - 58
  • [50] Design of Study 603: A multicentre, retrospective study in patients from korea with focal-onset seizures who converted to perampanel monotherapy
    Seo, D. W.
    Lee, J. W.
    Lee, Y.
    Lee, W. G.
    EPILEPSIA, 2022, 63 : 129 - 129